Caal Senators Squabbling Over Health Bills
More And More, States Are Becoming Battleground For Drug Pricing WarNews outlets report on stories related to pharmaceutical pricing.The Wall Street Journal:Drug Prices Under Fire, In The StatesAll eyes are on Washington as the Senate grapples with health care legislation. Investors in drug companies should give some attention to state capitals, where a wave o
brumate cooler f bills designed to limit drug price increases are under consideration. Maryland is the first of about 30 states weighing such bills to pass a new law on drug pricing. The law, scheduled to take effect in October, ou
stanley water bottle tlaws excessive price hikes on generics and gives Marylands attorney general sweeping powers to roll back price hikes and fine companies for violations.聽Bills with similar enforcement mechanisms have been introduced in several other states, including New York, Missouri, Massachusetts, Maine, and Rhode Island. Grant, 7/12 The Associated Press:West Virginia Joins Lawsuit Alleging Generic Price FixingWest Virginias attorney general has joined three other states and the District of Columbia to sue six generic drugmakers, alleging they conspired to hike prices for a common antibiotic and a diabetes medication. Attorney General Patrick Morrisey says the allegations will be pursued vigorously. 7/17 Stat:Sanofi Deni
hydro flask es Rejecting Army Request For A Fair Price On A Zika VaccineIn a series of letters to the U.S. Army and several senators, Sanofi is denying that it rejected so-called fair pricing for a Zika virus va Nfjv All US Olympians Are Fully Vaccinated; No One Requested Exemptions
Thursday, Jun 11 2009Congress Likely To Consider FDA Postmarket Prescription Drug Safety Surveillance in 2007FDA s tracking system for reporting adverse side effects of approved prescription medications is likely to be among a series of safety issues considered by Congress in 2007, when FDA reform legislation will be on the agenda, the Newark Star-Ledger reports Cohen, Newark Star-Ledger, 10/30 . A Government Accountability Office report released in April found that FDA lacks a clear and effective process for tracking safety issues related to approved drugs Kaiser Daily Health Policy Report, 4/24 . A gr
adidas originals oup of physicians in a recent Archives of Internal Medicine article came to similar conclusions, while an Institute of Medicine report released in September reported similar findings and made recommendations for improvement. Under the current system, drug makers are required to report serious adverse events to FDA within 15 days of discovery. In addit
owala website ion, manufacturers must report other problems quarterly for the first three years upon market arrival and annually thereafter. Hospitals, physicians and individuals also can submit reports. Curt Furberg, a member of the FDA s drug safety an
nike sb dunk d risk management advisory committee, estimates that reported events represent only about 10% of the serious side effects that occur annually and only about 1% of total side effects. Arthur Levin, director of the Center for Medical Consumers and the consumer representative on the FDA s drug
